- Home
- NUVB vs BALY Comparison
NUVB vs BALY Comparison
Compare NUVB & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BALY
- Stock Information
- Founded
- NUVB 2018
- BALY 2004
- Country
- NUVB United States
- BALY United States
- Employees
- NUVB N/A
- BALY 10000
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- NUVB Health Care
- BALY Consumer Discretionary
- Exchange
- NUVB Nasdaq
- BALY Nasdaq
- Market Cap
- NUVB 679.9M
- BALY 737.4M
- IPO Year
- NUVB N/A
- BALY N/A
- Fundamental
- Price
- NUVB $2.13
- BALY $14.39
- Analyst Decision
- NUVB Strong Buy
- BALY Hold
- Analyst Count
- NUVB 5
- BALY 7
- Target Price
- NUVB $8.20
- BALY $18.00
- AVG Volume (30 Days)
- NUVB 3.4M
- BALY 363.4K
- Earning Date
- NUVB 05-07-2025
- BALY 02-19-2025
- Dividend Yield
- NUVB N/A
- BALY N/A
- EPS Growth
- NUVB N/A
- BALY N/A
- EPS
- NUVB N/A
- BALY N/A
- Revenue
- NUVB $7,873,000.00
- BALY $2,481,783,000.00
- Revenue This Year
- NUVB $75.73
- BALY $3.06
- Revenue Next Year
- NUVB $440.21
- BALY N/A
- P/E Ratio
- NUVB N/A
- BALY N/A
- Revenue Growth
- NUVB N/A
- BALY 2.80
- 52 Week Low
- NUVB $1.54
- BALY $9.74
- 52 Week High
- NUVB $3.97
- BALY $18.38
- Technical
- Relative Strength Index (RSI)
- NUVB 59.35
- BALY 48.33
- Support Level
- NUVB $1.82
- BALY $14.00
- Resistance Level
- NUVB $2.23
- BALY $17.75
- Average True Range (ATR)
- NUVB 0.18
- BALY 1.91
- MACD
- NUVB 0.04
- BALY 0.10
- Stochastic Oscillator
- NUVB 84.78
- BALY 49.80
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, and entertainment company with a portfolio of casinos and resorts and a growing omnichannel presence. It provides customers with physical and interactive entertainment and gaming experiences, including traditional casino offerings, iGaming, online bingo, sportsbook, and free-to-play (F2P) games. The company owns and operates, several casinos across the United States, one golf course in New York, one horse racetrack in Colorado, and Aspers Casino in the United Kingdom. Its Interactive International division, an interactive gaming operator concentrated in Europe, operates a lottery management and services business. The company's reportable segments are Casinos and Resorts, which derive key revenue, International Interactive and North America Interactive.